bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
8.50
-0.73 (-7.91%)
At close: Dec 20, 2024, 4:00 PM
8.39
-0.11 (-1.29%)
After-hours: Dec 20, 2024, 5:59 PM EST
bluebird bio Employees
bluebird bio had 375 employees as of December 31, 2023. The number of employees increased by 52 or 16.10% compared to the previous year.
Employees
375
Change (1Y)
52
Growth (1Y)
16.10%
Revenue / Employee
$141,653
Profits / Employee
-$780,867
Market Cap
82.64M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
23andMe Holding Co. | 582 |
Karyopharm Therapeutics | 325 |
EDAP TMS | 307 |
Rani Therapeutics Holdings | 140 |
Adlai Nortye | 127 |
Aadi Bioscience | 89 |
Assertio Holdings | 53 |
Skye Bioscience | 11 |
BLUE News
- 13 days ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 14 days ago - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Business Wire
- 17 days ago - bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
- 17 days ago - bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire
- 24 days ago - FDA investigates risk of blood cancers from bluebird bio's gene therapy - Reuters
- 4 weeks ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 5 weeks ago - JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - Benzinga
- 5 weeks ago - bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript - Seeking Alpha